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Objective: Several studies have explored the prognostic values of HER2 expression in upper tract uro-
thelial carcinoma (UTUC), however, the results obtained are not consistent. We aimed to calculate the
clinical signiﬁcance of HER2 expression on the outcome of UTUC patients using a meta-analysis.
Materials and methods: Using published evidence, we performed a meta-analysis to examine the clinical
values of HER2 expression in patients with UTUC. Thirty-ﬁve articles from 679 articles related to the
epidermal growth factor receptor family expression assessment in UTUC patients were reviewed and
seven papers were found to be ﬁt for analyses. The estimates included the odds ratio (OR), distribution
related to stage and grade, hazard ratios (HRs), and 95% conﬁdence intervals (CIs) from survival analyses
of intravesical recurrence, progression, and overall survival (OS).
Results: The pooled results showed that HER2 expression is signiﬁcantly associated with higher stage,
but not with tumor grade in patients with UTUC (OR, 2.05; 95% CI, 1.15e3.68; p ¼ 0.016 and OR, 4.73; 95%
CI, 0.80e27.8; p ¼ 0.086, respectively). In addition, the pooled survival analyses demonstrated that HER2
expression yielded a worse recurrence-free survival in UTUC patients (HR, 4.32; 95% CI, 2.17e8.60;
p < 0.0001). However, there is lack of statistical signiﬁcance in terms of progression-free survival and OS
(HR, 2.08; 95% CI, 0.46e9.32; p ¼ 0.339 and HR, 1.06; 95% CI, 0.48e2.37; p ¼ 0.879, respectively).
Conclusion: Existing studies on UTUC are heterogeneous and limited. Our analysis suggests that HER2
expression plays an important role in cancer recurrence in the urinary bladder after the primary
treatment of UTUC.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Urothelial carcinomas (UCs) are composed of tumors arising
from the uroepithelia of the urinary tract, including the renal pelvis,
ureter, and urinary bladder. Upper tract urothelial carcinoma
(UTUC) refers to UCs of the renal pelvis or ureter.1 Several envi-
ronmental factors may contribute to the formation of UTUC,
including exposure to tobacco or aromatic amines, and consump-
tion of phenacetin or aristolochic acid-containing food or Chinese
herbs.2e4 Some factors are more speciﬁc for UTUC, whereas others
are similar to those associated with bladder cancer. In Taiwan, an
unusual higher incidence of UTUC had been reported in the pop-
ulation on the southwest coast,5 and recent research has suggestedollege of Medicine, National
Tainan 70401, Taiwan.
).
ciation. Published by Elsevier Taiw
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.doi.org/10.1016/j.urols.2015.that aristolochic acid-related Chinese medicine is responsible for
this phenomenon.4 Although only a few studies have focused on
UTUC owing to its rarity all over the world, whether or not UTUCs
and bladder cancer are disparate twins should be identiﬁed.6
Therefore, more evidence is required to understand the real char-
acteristics of this tumor at the clinical and molecular levels.
The epidermal growth factor receptor (EGFR) receptor family
(also known as the ErbB family) is a major class of receptor tyrosine
kinase proto-oncogenes. They play important roles in several
cellular processes, such as cell proliferation, migration, adhesion,
and, potentially, cellular transformation, including urothelial
carcinogenesis. The EGFR family consists of fourmembers, including
HER1 (EGFR and ErbB1), HER2 (erbB2 andHER2/neu), HER3 (ErbB3),
and HER4 (ErbB4).7 Through homodimerization or hetero-
dimerization by binding two monomers, the EGFR family signaling
regulates biological processes important for the pathogenesis of
human malignancies, including lung cancer, breast cancer, and
prostate cancer.8 Despite this, the clinical relevance of EGFRan LLC. All rights reserved.
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example, the EGFR/HER2-MAPK axis is important in human breast
cancer, whereas the kinase activity of the HER2/HER3 axis plays a
major role in DNA binding and androgen receptor stability in
prostate cancer.9 In terms of bladder cancer, a previous meta-
analysis reported that the overall risks of disease progression for
patients with EGFR or HER2 overexpression were 4.5 [95% conﬁ-
dence interval (CI): 2.5e8.4] and 1.1 (95% CI: 0.6e1.9), and the risks
of mortality were 3.0 (95% CI: 1.6e5.9) and 1.1 (95% CI: 1.0e1.2),
respectively.10 In addition, a recentmeta-analysis showed thatHER2
expression was signiﬁcantly associated with tumor grade [high
grade vs. low grade: odds ratio (OR) 4.08; 95% CI 1.29e12.93] and
lymph node metastasis (positive vs. negative: OR 1.71; 95% CI
1.07e2.75).11
To investigate the clinical relevance of HER2 expression in UTUC
patients, we systematically reviewed papers published in the past 3
decades on EGFR family expression and their impact on patient
prognosis. Our objectives were to conﬁrm the signiﬁcance of HER2
expression in predicting subsequent bladder cancer recurrence,
progression, and mortality in UTUC patients by conducting a meta-
analysis of available estimates.
2. Materials and methods
2.1. Search strategy and selection criteria
Original articles published between January 1990 and January
2015 and showing prognostic signiﬁcance or clinical relevance of
expression or ampliﬁcation of the EGFR family in patients with
bladder cancer or UTUC were systematically reviewed. Using the
keywords “EGF,” “EGF-R,” “HER2,” “HER3,” “HER4,” “c-erb-B1,” “c-
erb-B2,” “c-erb-B3,” “c-erb-B4,” “neu,” “epidermal growth factor,”
“bladder neoplasm,” “urothelial carcinoma,” “upper tract urothelial
carcinoma,” or “transitional cell carcinomas-in-humans,” we
identiﬁed 679 relevant articles in the PubMed database. The
number of studies was reduced to 35 by limiting the search to
“renal pelvis,” “ureter,” or “upper tract.” Duplicate data, identiﬁed
in the same cohort by reviewing the interstudy similarities of in-
vestigators, source of patients, recruitment period, or inclusion
criteria, were excluded from this analysis.
2.2. Data extraction, handling, and analyses
The database was created by including relevant data based on
study design, patient outcomes, tumor characteristics, statistical
analyses, biological samples, analytical methods, and the status of
expression or gene ampliﬁcation of each EGFR family member. The
data were extracted using the following methods. Because some
articles only provided the p values or statements of whether results
were signiﬁcant, the analyses of subsequent bladder cancerTable 1
Characteristics of included studies.
References No. of patients Stage IHC Method or Aba
Imai et al (1995)12 30 Ta-3 Rabbit c-erbB2 pAb (Nichirei, Tokyo
Langner et al (2005)30 53 T1-3 HercepTest (Dako, Hamburg, Germa
Tsai et al (2005)31 94 Ta-4 Mouse anti-erbB2 mAb (CB11; BioG
Izquierdo et al (2010)32 100 Ta-4 Rabbit c-erbB2 pAb (A0485; Dako, D
Galanakis et al (2013)33 99 Ta-4 Mouse anti-erbB2 mAb (CB11; Bioc
Ehsani et al (2014)34 46 Ta-4 Mouse anti-HER2 mAb (Dako, Carp
Sasaki et al (2014)35 171 Ta-4 Anti-HER-2/neu mAb (4B5; Rochec,
Ab ¼ antibody; IHC ¼ immunohistochemistry; mAb ¼ monoclonal antibody; NA ¼ not a
a The used antibody or tested method.
b % positive cells or scoring.
c Ventana Medical Systems Inc.
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original reports. In brief, “recurrence” was deﬁned as a tumor that
was found in the urinary bladder after deﬁnite surgery, and “dis-
ease progression”was deﬁned as any tumor with a higher T stage in
the local tumor, node, or metastasis. The p values (or statements of
signiﬁcance) were extracted from association analyses (such as c2
test, Student t test, ManneWhitney U test, and logistic regression),
and the risk estimates and 95% CIs were extracted from univariate
(KaplaneMeier curves and the log-rank test) and multivariate
survival (Cox regression) analyses.
2.3. Statistical analysis
For recurrence-free survival (RFS), progression-free survival
(PFS), and overall survival (OS), hazard ratios (HRs) and their cor-
responding 95% CIs were pooled for the meta-analysis. The asso-
ciation between HER2 overexpression and histological grade and
tumor stage were pooled and calculated using ORs and their CIs.
The Wolf method was used to combine the risk estimates by
applying the inverse of variance as the weighting factor. Potential
sources of heterogeneity were investigated using graphical
methods, such as the funnel plot. A ﬁxed-effects model was used
when I2 tests showed <50% heterogeneity. In cases of substantial
heterogeneity, random-effect models were used. Sensitivity anal-
ysis was conducted by sequentially omitting individual studies to
validate the stability of the outcomes, and publication bias was
visually evaluated using funnel plot. The extent to which the
combined risk estimate was affected by individual study was
examined by consecutively omitting every study from the meta-
analysis. Meta-regression was used to explain the potential het-
erogeneity arising from the same characteristics included in the p
value analysis. The publication bias was investigated using Egger's
and Begg's graphical methods. The analyses were done using
Comprehensive Meta Analysis Version 2 (Biostat, Inc., Englewood,
NJ, USA). Signiﬁcance was set at p < 0.05 (two sided).
3. Results
3.1. Study selection and characteristics
A total of 679 publications were initially identiﬁed through
database searching, and 35 potential relevant reports remained
after removing irrelevant or duplicate publications based on title
and abstract screening. Among 28 full-text articles that were
available for eligibility assessment, 21 articles were further
excluded because they lacked key information for estimating OR, or
HR and seven eligible articles were ﬁnally identiﬁed (Table 1). The
ﬂow diagram shows the article selection process (Fig. 1). The main
characteristics of the included studies are summarized in Table 1.
Among the seven studies, a total of 593 UTUC patients (rangingCutoffb Expression (%) Follow up (mo),
median (range)
, Japan) >25% 43.3 22.2 (3.9e78.2)
ny) >þ2 52.8 26 (1e148)
enex, San Ramon, CA) >5% 13.8 40 (1e177)
enmark) NA 10.0 33.03 (0.3e182.7)
are Medical, Concord, CA, USA) >5% 64.8 52.5 (1e127)
interia, CA, USA) >þ2, >10% 73.9 NA
Tokyo, Japan) >þ2 18.1 NA
vailable; pAB ¼ polyclonal antibody.
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Fig. 1. Methodological ﬂow diagram of the meta-analysis. HR ¼ hazard ratio;
OR ¼ odds ratio.
Fig. 2. Forest plots of association of HER2 expression with (A) tumor stage and (B) histologica
intervals (CIs) for UTUC patients according to HER2 expression.
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included studies were retrospective cohort studies.
3.2. Study ﬁndings and meta-analysis
3.2.1. Correlation of HER2 with tumor stage and histological grade
The HER2-positive rates across the seven studies ranged from
13.8% to 73.9%, with a pooled positive rate of 32.5% (193/593). Five
studies reported the association of HER2 expression with tumor
stage and four studies involved the histological grade. Moderate
heterogeneity (I2 ¼ 38%; p ¼ 0.168) and high heterogeneity
(I2 ¼ 57%; p ¼ 0.070) regarding tumor stage and histological-grade
status, respectively, were determined among the studies. Thus, the
ﬁxed-effects and random-effects models were, respectively, used to
pool the data for the tumor stage and histological grade results.
Meta-analysis showed that the HER2 expression was signiﬁcantly
associated with tumor stage (pooled OR, 2.05; 95% CI, 1.15e3.68;
p ¼ 0.016; Fig. 2A) and histological grade (pooled OR, 4.73; 95% CI,
0.80e27.8; p ¼ 0.086; Fig. 2B).
3.2.2. Correlation of HER2 with survival
For each survival analysis (RFS, PFS, and OS), three individual
studies reported each own outcome. High heterogeneity (I2, 69%
and 63%; p values, 0.038 and 0.067, respectively) and low hetero-
geneity (I2 ¼ 0%; p ¼ 0.792) regarding PFS, OS, and RFS outcomes,l grading in upper tract urothelial carcinomas (UTUCs). Odds ratios and 95% conﬁdence
xpression in patients with upper tract urothelial carcinoma: A meta-
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Fig. 3. Forest plots of prognostic signiﬁcance of HER2 expression on (A) intravesical recurrence, (B) disease progression, and (C) overall survival. Hazard ratios and 95% conﬁdence
intervals (CIs) for upper tract urothelial carcinoma patients according to HER2 expression.
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random-effects and ﬁxed-effects models were, respectively, used to
pool the data for the PFS, OS, and RFS results. Meta-analysis showed
that the HER2 expression was signiﬁcantly associated with
decreased RFS (pooled HR, 4.32; 95% CI, 2.17e8.60; p < 0.0001;
Fig. 3A). However, there is lack of statistical signiﬁcance in terms of
PFS and OS (HR, 2.08; 95% CI, 0.46e9.32; p ¼ 0.339 and HR, 1.06;
95% CI, 0.48e2.37; p ¼ 0.879, respectively; Figs. 3B and 3C).
3.2.3. Sensitivity analysis and publication bias
Sensitivity analysis showed that the study result of Imai et al12 is
inﬂuencing the meta-analysis result. After excluding this study, thePlease cite this article in press as: Chen C-H, et al., Signiﬁcance of HER2 e
analysis, Urological Science (2015), http://dx.doi.org/10.1016/j.urols.2015pooled correlation with histological grade became signiﬁcant
(pooled OR, 10.6; 95% CI, 3.2e35.4; p < 0.0001). For publication bias
analysis, funnel plots for the included studies showed no obvious
sign of asymmetry.
4. Discussion
This meta-analysis revealed that estimates of the signiﬁcance of
HER2 expression vary substantially between studies in patients
with UTUC, which is somewhat unlike bladder cancer.10,11 HER2
expression is predictive of intravesical recurrence in UTUC patients
following nephroureterectomy and is signiﬁcantly associated withxpression in patients with upper tract urothelial carcinoma: A meta-
.04.002
C.-H. Chen et al. / Urological Science xxx (2015) 1e6 5higher tumor stage. Nonetheless, HER2 expression did not show
any signiﬁcant value in predicting UTUC patients' OS and progres-
sion. By contrast, HER2 expression is weakly predictive of cancer
mortality and signiﬁcantly associated with nodal metastasis in
bladder cancer patients.10,11,13 This might be one of the reasons why
only few studies have examined the implications of HER2 expres-
sion in UTUCs. Therefore, these ﬁndings should be interpreted
carefully because relatively few studies were eligible for analysis.
In 1992, HER2 gene ampliﬁcation was ﬁrst reported to exist in
UTUC and urinary bladder cancer.14 Along with the investigation of
EGF, EGFR, and HER2 expressions in bladder cancer,15,16 Imai et al12
reported 2-decades-ago that the expressions of EGFR and c-erbB2
can predict subsequent bladder cancer tumor recurrence following
primary treatment. Since then, only limited studies have discussed
the clinical signiﬁcance or biological role of HER2 protein in UTUCs.
Therefore, our ﬁndings can provide more strengthening informa-
tion about the signiﬁcance of HER2 expression in UTUC.
Although several studies have reported that overexpressed
mutant EGFR family members drive the development of human
cancers, such as breast cancer,17 little is known about the molecular
mechanism of EGFR family signaling in UTUC. Recently, aristolochic
acid has been shown to be an important chemical carcinogen for
UTUC in Taiwan and the Balkan areas.18,19 It is well-known that
aristolochic acid can induce renal ﬁbrosis-related nephropathy in
rats and humans20; however, it is still unclear how this substance
induces the formation of this malignancy, or how it inﬂuences the
molecular signal transduction through aristolochic acideDNA
adduct. Nevertheless, EGF/EGFR signaling is responsible for the
promotion of tumor growth factor-b-dependent renal ﬁbrosis after
acute kidney injury through an unpredicted signaling activation
such as extracellular signal-regulated kinase.21,22 Therefore, it is
worth investigating the biological role of EGFR family signaling
such as EGFR or HER2 expression in the formation of aristolochic
acid-related UTUC.
Therewere several discouraging results of clinical trials focusing
on blockading EGFR or HER2 signaling in treating UC of urinary
bladder or UTUCs,23,24 despite evidence of the signiﬁcance of EGFR
or HER2 signaling in bladder cancer. Little progress is noted in
treating advanced UC compared with other types of malignancies,
evenwith chemotherapy,25,26 although some small series showed a
promising sensitivity to everolimus in bladder cancer with tuber-
ous sclerosis complex 1 mutation.27 Recent genomic studies
demonstrated that diverse genomic aberrations existed in bladder
UC,28,29 and that bladder cancers split into three pan-cancer sub-
types. However, the question of whether UTUCs exhibit similar
biological characteristics as those of bladder cancer remains
unanswered. The answer to this question will conﬁrm whether or
not UTUC and bladder cancer are disparate twins. Therefore, it is
worth further investigating the difference between these twins or
the inﬂuence of aristolochic acid.
There were some limitations or inconsistencies in this meta-
analysis. For example, there was an inconsistency regarding the
efﬁcacy of HER2 expression in predicting the risk of progression
and mortality in UTUC patients except for intravesical recurrence.
Such incongruity is somewhat consistent with the discrepancies in
this meta-analysis. The factors include a wide spectrum of disease
statuses (Ta-4) in limited cases, variability in the immunostaining
assays used, biases from scoring, cutoff points, and interpretation.
There are additional contributing factors, namely, methods used for
detecting events of interest, treatment methods, the length of
follow up, and inconsistency in the inclusion of clinical and path-
ological factors for multivariate analysis. Finally, the risks calculated
in our meta-analysis may be overestimated by reporting biases
because HRs and 95% CIs were not described when associations
were not signiﬁcant or published in the local journal.Please cite this article in press as: Chen C-H, et al., Signiﬁcance of HER2 e
analysis, Urological Science (2015), http://dx.doi.org/10.1016/j.urols.2015.5. Conclusion
In conclusion, this meta-analysis has revealed a signiﬁcant as-
sociation between HER2 expression, and bladder cancer recur-
rence and tumor stage in UTUC patients. Considering current
molecular information, assessing HER2 expression provided only
limited prognostic information for UTUC patients. Although being
considered a twin with bladder cancer, little attention has been
paid to studying UTUC. Limited information is available on the
molecular carcinogenesis of the aristolochic acid-related UTUCs,
especially about its relationship with EGFR or HER2 signaling.
Therefore, there is a need for more additional investigations in this
regard.Conﬂicts of interest
All contributing authors declare no conﬂicts of interest.References
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